ABEONA THERAPEUTICS INC (ABEO) Stock Fundamental Analysis

NASDAQ:ABEO • US00289Y2063

5.2 USD
-0.1 (-1.89%)
At close: Feb 26, 2026
5.2 USD
0 (0%)
After Hours: 2/26/2026, 8:09:06 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ABEO. ABEO was compared to 521 industry peers in the Biotechnology industry. While ABEO seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ABEO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year ABEO has reported negative net income.
  • In the past year ABEO has reported a negative cash flow from operations.
  • ABEO had negative earnings in each of the past 5 years.
  • In the past 5 years ABEO always reported negative operating cash flow.
ABEO Yearly Net Income VS EBIT VS OCF VS FCFABEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • ABEO has a better Return On Assets (35.63%) than 98.66% of its industry peers.
  • ABEO's Return On Equity of 48.09% is amongst the best of the industry. ABEO outperforms 98.46% of its industry peers.
Industry RankSector Rank
ROA 35.63%
ROE 48.09%
ROIC N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ABEO Yearly ROA, ROE, ROICABEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • With an excellent Profit Margin value of 20587.50%, ABEO belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
  • The Operating Margin and Gross Margin are not available for ABEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 20587.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABEO Yearly Profit, Operating, Gross MarginsABEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ABEO has more shares outstanding
  • The number of shares outstanding for ABEO has been increased compared to 5 years ago.
  • The debt/assets ratio for ABEO is higher compared to a year ago.
ABEO Yearly Shares OutstandingABEO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ABEO Yearly Total Debt VS Total AssetsABEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • ABEO has an Altman-Z score of -1.67. This is a bad value and indicates that ABEO is not financially healthy and even has some risk of bankruptcy.
  • ABEO has a Altman-Z score of -1.67. This is comparable to the rest of the industry: ABEO outperforms 51.82% of its industry peers.
  • ABEO has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.06, ABEO perfoms like the industry average, outperforming 40.12% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -1.67
ROIC/WACCN/A
WACC8.69%
ABEO Yearly LT Debt VS Equity VS FCFABEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • ABEO has a Current Ratio of 9.74. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
  • ABEO's Current ratio of 9.74 is amongst the best of the industry. ABEO outperforms 80.04% of its industry peers.
  • ABEO has a Quick Ratio of 9.53. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 9.53, ABEO belongs to the best of the industry, outperforming 80.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.74
Quick Ratio 9.53
ABEO Yearly Current Assets VS Current LiabilitesABEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • ABEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.38%, which is quite impressive.
  • ABEO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.13%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ABEO will show a very strong growth in Earnings Per Share. The EPS will grow by 28.39% on average per year.
  • The Revenue is expected to grow by 412.56% on average over the next years. This is a very strong growth
EPS Next Y172.22%
EPS Next 2Y40.32%
EPS Next 3Y37.35%
EPS Next 5Y28.39%
Revenue Next Year6533.33%
Revenue Next 2Y3247.96%
Revenue Next 3Y1168.37%
Revenue Next 5Y412.56%

3.3 Evolution

ABEO Yearly Revenue VS EstimatesABEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
ABEO Yearly EPS VS EstimatesABEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ABEO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABEO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABEO Price Earnings VS Forward Price EarningsABEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABEO Per share dataABEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • ABEO's earnings are expected to grow with 37.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.32%
EPS Next 3Y37.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ABEO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (2/26/2026, 8:09:06 PM)

After market: 5.2 0 (0%)

5.2

-0.1 (-1.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-18
Inst Owners66.83%
Inst Owner Change11.05%
Ins Owners5.16%
Ins Owner Change11.38%
Market Cap281.79M
Revenue(TTM)400.00K
Net Income(TTM)82.35M
Analysts86.67
Price Target21.06 (305%)
Short Float %31.09%
Short Ratio12.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.03%
Min EPS beat(2)-36.14%
Max EPS beat(2)66.19%
EPS beat(4)3
Avg EPS beat(4)31.61%
Min EPS beat(4)-36.14%
Max EPS beat(4)66.19%
EPS beat(8)4
Avg EPS beat(8)4.74%
EPS beat(12)7
Avg EPS beat(12)27.06%
EPS beat(16)9
Avg EPS beat(16)18.42%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.4%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-33.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-75.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 704.47
P/FCF N/A
P/OCF N/A
P/B 1.65
P/tB 1.65
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-1.52
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0.01
BVpS3.16
TBVpS3.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 35.63%
ROE 48.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 20587.5%
GM N/A
FCFM N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 476.46%
Cap/Sales 1857%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.74
Quick Ratio 9.53
Altman-Z -1.67
F-Score6
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)46.91%
Cap/Depr(5y)59.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.13%
EPS Next Y172.22%
EPS Next 2Y40.32%
EPS Next 3Y37.35%
EPS Next 5Y28.39%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year6533.33%
Revenue Next 2Y3247.96%
Revenue Next 3Y1168.37%
Revenue Next 5Y412.56%
EBIT growth 1Y-36.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-95.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79.43%
OCF growth 3YN/A
OCF growth 5YN/A

ABEONA THERAPEUTICS INC / ABEO FAQ

Can you provide the ChartMill fundamental rating for ABEONA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ABEO.


Can you provide the valuation status for ABEONA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to ABEONA THERAPEUTICS INC (ABEO). This can be considered as Overvalued.


How profitable is ABEONA THERAPEUTICS INC (ABEO) stock?

ABEONA THERAPEUTICS INC (ABEO) has a profitability rating of 2 / 10.